Join to View Full Profile
3181 SW Sam Jackson Park Rd# OhsuPortland, OR 97239
Phone+1 503-494-7999
Dr. Medvedova is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2007 - 2010- UMass Chan Medical SchoolResidency, Internal Medicine, 2004 - 2007
Comenius UniversityClass of 2002
Certifications & Licensure
OR State Medical License 2013 - 2025
MA State Medical License 2009 - 2014
CT State Medical License 2010 - 2012
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.Smith Giri, Binod Dhakal, Natalie S Callander, Eva Medvedova, Kelly Godby
Blood. 2025-04-07 - Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.Luciano J Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R Dholaria, Kelly N Godby
Blood Cancer Journal. 2025-02-05 - 1 citationsDaratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, Yael C Cohen, Vania Hungria
The New England Journal of Medicine. 2024-12-09
Abstracts/Posters
- Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...Eva Medvedova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...Eva Medvedova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
